Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

PHASE3CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

November 26, 2013

Primary Completion Date

October 27, 2016

Study Completion Date

October 27, 2016

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Matching Placebo

twice daily dosing

DRUG

Nintedanib

gelating capsule

Trial Locations (25)

11501

Winthrop University Hospital, Mineola

29406

Lowcountry Lung and Crit Care, Charleston

34098

Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul

34239

Clinical Research Center Sarasota Memorial Hosptial, Sarasota

34760

Yedikule Gog. Hst. EAH, Istanbul

34844

Sureyyapasa Gogus Hast. ve Gogus Cer. Egit. ve Aras. Has., Istanbul

35100

Ege Universitesi T.F., Izmir

35110

Dr.Suat Seren EAH, Izmir

40503

Baptist Health Lexington, Lexington

43608

ID Clinical Research, LTD, Toledo

55407

Minnesota Lung Research, Minneapolis

60076

Chest Medicine Clinical Services, Skokie

75246

Annette C & Harold C Simmons Transplant Institute, Dallas

97220

The Oregon Clinic, Portland

06810

Western CT Medical Group, P.C., Danbury

03756

Dartmouth-Hitchcock Medical Center, Lebanon

T6G 2G3

University of Alberta Hospital (University of Alberta), Edmonton

V5Z 1M9

Vancouver General Hospital, Vancouver

V6Z 1Y6

St. Paul's Hospital, Vancouver

R2K 3S8

Concordia Hospital, Winnipeg

B3H 3A7

QEII Health Sciences Centre (Dalhousie University), Halifax

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

J1H 5N4

CHUS Fleurimont, Sherbrooke

01330

Cukurova Universitesi Tip Fakultesi Gog. Hast. Anabilim Dali, Adana

06100

Ankara Universitesi Tip Fakultesi, Ankara

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01979952 - Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter